Vitaprost lyophilisate for injection solution 2 mg bottle No. 10

Instructions Vitaprost lyophilisate for injection solution 2 mg bottle No. 10

Composition

active ingredient: 1 bottle contains lyophilized from an aqueous solution of bovine prostate extract obtained by extraction, calculated as polypeptides, not less than 2.0 mg;

excipient: glycine.

Dosage form

Lyophilisate for solution for injection.

Main physicochemical properties: amorphous powder or porous mass of white or white with a yellowish tinge.

Pharmacotherapeutic group

Drugs used in benign prostatic hypertrophy. ATX code G04C X.

Pharmacological properties

Pharmacodynamics.

Vitaprost has a specific organotropic effect on the prostate gland. In the case of the latter disease, the drug as a means of pathogenetic therapy normalizes the processes of microcirculation and platelet-vascular hemostasis, reduces or eliminates tissue edema, leukocyte infiltration (including reducing the content of leukocytes in the gland's secretion), has an indirect bacteriostatic effect on the microflora of the secretion, reduces the titer of the detected pathogen up to absolute sterility or inhibits the viability of microorganisms. Vitaprost normalizes spermatogenesis (increases the number and mobility of sperm), has a modulating effect on the state of T- and B-lymphocytes, regulates the tone of the bladder muscles, including the tone of the detrusor, increases the body's nonspecific resistance.

Pharmacokinetics.

The peptide drug Vitaprost is broken down by cellular proteases to amino acids. Vitaprost and its metabolites are excreted in the urine. The drug has no cumulative effect.

Indication

Chronic prostatitis, prostate adenoma, age-related dysfunction of its functions and related disorders of the act of urination, complications after prostate surgery; interoceptive copulatory dysfunction; male infertility.

Contraindication

Hypersensitivity to the components of the drug and bovine proteins.

Interaction with other medicinal products and other types of interactions

Didn't study.

Application features

When treating with the drug, it is recommended to analyze clinical indicators of prostate activity (prostate-specific antigen).

Use during pregnancy or breastfeeding

The drug is not used in women.

The ability to influence the reaction speed when driving or working with other mechanisms

Not studied.

Method of administration and doses

Use for the treatment of adults, including elderly men. Administer intramuscularly. Before use, dissolve the contents of the vial in 1-2 ml of water for injection or 0.9% sodium chloride solution, or 0.5% novocaine solution. If novocaine is used as a solvent, it is necessary to take into account information on the safety of novocaine. The drug is administered daily, 1-2 vials once a day. The course of treatment is 5-10 days. If necessary, repeat the course (after 1-6 months).

Children

The drug is not used in children.

Overdose

It was not studied.

Side effects

Allergic reactions are possible, including itching, rash; changes at the injection site.

Expiration date

3 years.

Storage conditions

Store in the original packaging to protect from light at a temperature not exceeding 25 °C.

Incompatibility

The drug should not be mixed with other drugs in the same syringe. Use only recommended solvents.

Packaging

5 vials of lyophilisate in a blister, 2 blisters in a pack.

Vacation category

According to the recipe.

Producer

LLC "FZ "BIOPHARMA", Ukraine.

Address

Ukraine, 09100, Kyiv region, Bila Tserkva, Kyivska st., 37.